The National Foundation for Infectious Diseases recently released a white paper summarizing a panel discussion of national pediatric infectious disease experts on rotavirus. The paper, which was co-sponsored by US drug major Merck & Co, addresses the latest scientific information available on rotavirus, including epidemiology, classification, prevention and treatment of the disease. In the midst of the rotavirus season, this paper may serve as a valuable resource to your readers. For a free copy of the white paper, visit: http://www.nfid.org/pdf/rotavirus_paper.pdf.
Rotavirus is a leading cause of acute gastroenteritis in infants and young children worldwide, infecting nearly all children by the age of 5. The most severe cases occur among children 6 to 24 months of age, with symptoms including fever, vomiting and watery diarrhea. In serious cases, repeated episodes of diarrhea or vomiting can lead to loss of fluid and electrolytes, placing the child at risk for severe dehydration and death.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze